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Abstract
Background
To date, over 150 possible uremic solutes have been listed, but their role in the progression
of CKD is largely unknown. Here, the association between a selected panel of uremic sol-
utes and progression in CKD patients was investigated.
Methods
Patients from the MASTERPLAN study, a randomized controlled trial in CKD patients with a
creatinine clearance between 20 and 70 ml/min per 1.73m2, were selected based on their
rate of eGFR decline during the first five years of follow-up. They were categorized as rapid
(decline >5 ml/min per year) or slow progressors. Concentrations of eleven uremic solutes
were obtained at baseline and after one year of follow-up. Logistic regression was used to
compare the odds for rapid to slow progression by uremic solute concentrations at baseline.
Variability in uremic solute levels was assessed using scatter plots, and limits of variability
were calculated.
Results
In total, 40 rapidly and 40 slowly progressing patients were included. Uremic solutes were
elevated in all patients compared to reference values for healthy persons. The serum levels
of uremic solutes were not associated with rapid progression. Moreover, we observed sub-
stantial variability in solute levels over time.
Conclusions
Elevated concentrations of uremic solutes measured in this study did not explain differences
in rate of eGFR decline in CKD patients, possibly due to lack of power as a result of the small
sample size, substantial between patient variability, and variability in solute concentrations
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over time. The etiology of intra-individual variation in uremic solute levels remains to be
elucidated.
Introduction
Patients with advanced chronic kidney disease (CKD) suffer from a wide array of symptoms,
including anemia, bone-mineral disorders, reduced cognitive function and hypertension.
These symptoms are thought to be caused, at least partially, by the accumulation of so-called
uremic solutes.
Vanholder et al. defined uremic solutes as those compounds which accumulate in blood and
tissues during the development of end stage kidney disease and which have an impact on bio-
logical functions.[1] To date, the European Uremic Solute Workgroup (EUTox) lists over 150
of such retention solutes.[2, 3] Moreover, solutes classified by the EUTox project may be ele-
vated not only in dialysis patients, but in patients with less advanced stages of CKD as well.[4, 5]
Evidence suggests that uremic solutes can induce apoptosis and epithelial-to-mesenchymal
transition in the proximal tubule.[6–8] In addition, uremic solutes are substrates but also
inhibitors of tubular transport proteins that are responsible for the excretion of drugs, solutes
and waste products.[5, 9–16] Furthermore, uremic solutes can alter mitochondrial function-
ing, resulting in increased superoxide and hydroxyl radical production and increased rates of
apoptosis. [17, 18] Uremic solutes have been associated with clinical outcome as well. A recent
review suggests a major role for protein-bound uremic solutes in cardiovascular morbidity
and mortality.[19] Moreover, sequestration of uremic solutes in the intestine resulted in a
slower eGFR decline in CKD patients.[20] However, this is indirect evidence for a role of ure-
mic solutes at best. Therefore, we investigated whether a selection of uremic solutes were
determinants for renal function deterioration in patients with moderate CKD.
Materials and Methods
Study population
The MASTERPLAN study was a randomized controlled trial (ISRCTN registry number
73187232) that compared a multifaceted treatment approach with the aid of a nurse practi-
tioner to standard care by a nephrologist on cardiovascular outcome in patients with CKD.
[21] In total, 788 adult patients with CKD and an estimated creatinine clearance between 20
and 70 ml/min per 1.73m2 were included. All patients provided written informed consent, and
the study was approved by the medical ethics committee of the University Medical Centre
Utrecht. All patients were treated according to the same guidelines. However, the nurse practi-
tioners were specifically trained in motivational interviewing to enhance compliance and pro-
mote life-style changes.[21] We performed a nested case-control study. Patients who received
a transplant before baseline were excluded from our selection. In order to evaluate the change
in uremic solute concentration over time, only patients with at least one year of follow-up
were included. Rapid progression was defined according to KDIGO guidelines as a decline of
more than 5 ml/min per 1.73m2 per year. A single control from the remaining patients was
selected at random for each rapid progressor.
Data collection
Data collection has been described in detail previously.[21] At baseline and annual intervals
blood samples were drawn using EDTA tubes and stored at -80˚C. Blood samples collected at
Uremic Solutes in CKD
PLOS ONE | DOI:10.1371/journal.pone.0168117 December 29, 2016 2 / 16
genzyme.nl), Pfizer Netherlands, Dr Arjan D van
Zuilen, (www.pfizer.nl), and Sanofi-Aventis
Netherlands, Dr Arjan D van Zuilen, (www.sanofi.
nl). The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The MASTERPLAN study
was supported by grants from the Dutch Kidney
foundation (www.nierstichting.nl, NSN PV01) and
the Netherlands Heart Foundation (www.
hartstichting.nl, Hartstischting, 2003B261). H. A.
M. Mutsaers was supported by the Dutch Kidney
Foundation (grant number IK08.03; www.
nierstichting.nl). Unrestricted grants were provided
by Amgen Netherlands (www.amgen.nl), Genzyme
Netherlands (www.genzyme.nl), Pfizer Netherlands
(www.pfizer.nl) and Sanofi-Aventis Netherlands
(www.sanofi.nl). There are no patents, products in
development or marketed products to declare. This
does not alter our adherence to all the PLOS ONE
policies on sharing data and materials, as detailed
online in the guide for authors.
one year were used to determine follow-up uremic solute concentrations. Information on
medical history, physical activity, diet and medication use was obtained using questionnaires.
Patients underwent physical examination. Standard laboratory measurements were performed
at local laboratories. However, serum creatinine values were calibrated to the central study
laboratory.
Uremic solute measurements
During the study, samples were analyzed in nine separate batches, each batch including both
the baseline and follow-up sample for an individual patient to reduce analytic variation. Fur-
thermore, every batch included both rapid and slow progressors to ensure statistical adjust-
ment for potential batch effects was possible. We selected a panel of eleven well known toxins
based on previous work. The selected solutes inhibit tubular transport activity,[5] are associ-
ated with epithelial phenotypic changes in the renal tubule,[4] or reduce mitochondrial activity
in tubular epithelial cells.[18] Uremic solute concentrations were determined with liquid chro-
matography-tandem mass spectrometry (LC-MS/MS) as described previously.[22] Before
chromatography an aliquot of plasma was diluted in H2O (1:1) and deproteinized with per-
chloric acid (final concentration 3.3% (v/v)). Next, samples were centrifuged at 12,000 x g for 3
min and the clear supernatant was injected into the UPLC-MS/MS system that consisted of an
Accela HPLC system coupled to a TSQ Vantage triple quadropole mass spectrometer (Thermo
Fischer Scientific, Breda, the Netherlands) equipped with a C18 UPLC column (Acquity
UPLC HSS T3 1.8 um; Waters, Milford, MA). The autosampler temperature was set at 8˚C
and the column temperature at 40˚C. The flow rate was 350 μl/min. Eluent solvent A consisted
of 10 mM NH4-acetate, solvent B was 5 mM NH4-acetate and 0.1% formic acid and solvent C
was 100% methanol. Detection of the components was based on isolation of the deprotonated
(negative electrospray; [M-H]-) or protonated molecular ion (positive electrospray; [M+H]+)
and subsequent MS/MS fragmentations and a selected reaction monitoring (SRM) were car-
ried out. The UPLC-MS/MS operating conditions and SRM transitions used for parent com-
pounds and ion products were optimized for each component. A calibration curve was used to
quantify the solute levels in the samples. Acquired data were processed with Thermo Xcaliber
software (Thermo scientific).
Statistical analyses
Descriptive data are presented as frequencies and proportions, means and standard deviations
for normally distributed variables or medians and inter quartiles ranges if the distribution was
skewed. X2, Wilcoxon ranksum, and t-tests were used to compare baseline covariates between
groups. Reference concentrations for healthy controls were obtained from the Human Meta-
bolome database.[23] We compared the mean concentrations in our population to these val-
ues. Correlations between baseline covariates and uremic solute levels were obtained from a
linear regression and calculated as the square root of R2.
The variation in serum levels of uremic solutes was assessed with scatter plots and Bland-
Altman plots. The limits of variation were calculated as 1.96 times the standard deviation of
the average difference in baseline and follow-up concentration. As the variation in concentra-
tion increased with uremic solute level, we took the natural logarithm of the baseline and fol-
low-up concentrations. Back transformation of the difference and its limits allowed us to
interpret the variation in uremic solute concentrations as ratios.[24]
Logistic regression was used to estimate odds ratios for rapid progression by uremic solute
level. We used the dagitty.net tool to create a causal diagram and identify the minimal variable
set to be included into the logistic regression in order to obtain an unbiased estimate of the
Uremic Solutes in CKD
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association between uremic solute concentrations and progression of CKD. The causal dia-
gram can be found in the supplements available online (S1 Fig directed acyclical graph for the
analysis of uremic solutes as determinants of rapid progression in CKD).
Results
Baseline characteristics
Of the 788 patients included in the MASTERPLAN trial, 110 patients had received a kidney
transplant prior to baseline and 48 patients had less than one year follow-up and were there-
fore excluded. In total, 47 of the included patients showed rapid progression. We were unable
to retrieve samples for seven of them. Controls for the remaining 40 rapid progressors were
randomly selected. Fig 1 shows the flow chart for patient inclusion. Total follow-up duration
was 4.4 (inter quartile range 2.9 to 5.0) years. Table 1 shows the baseline characteristics for
both groups. The majority of included patients were male and mean age was 63 years in the
slow progressors compared to 55 years in the rapid progressors. Mean eGFR was 36 ml/min
per 1.73m2 for both slow and rapid progressors. In general, patients with rapid progression
were younger, were more likely to have congenital kidney disease (86% of whom had cystic
kidney disease), had higher proteinuria and uric acid, and a lower serum albumin concentra-
tion. Only the difference in baseline serum kynurenic acid concentration, which was higher in
rapid progressors, approached statistical significance (Table 2). Levels of uremic solutes in our
study sample were generally elevated compared to healthy individuals, with the exception of
kynurenic acid, which was lower compared to healthy individuals.
Association of uremic solute concentrations and baseline covariates
We performed exploratory analyses to determine associations between uremic solute con-
centration and known risk factors for the development and progression of CKD. Fig 2
shows correlations between uremic solutes and baseline covariates. Remarkably, CMPF
concentration only weakly correlated to other uremic solute concentrations. Hippuric acid
was statistically significantly correlated with kynurenic acid. Indole-3-acetic acid corre-
lated with p-cresyl sulfate. Indoxyl sulfate associated with p-cresyl sulfate and its glucuro-
nide and phenyl sulfate. Kynurenic acid correlated with kynurenine, quinolinic acid in
addition to its correlation with hippuric acid. Kynurenine associated with quinolinic acid
as well. Finally, p-cresyl glucuronide and p-cresyl sulfate concentrations correlated too.
Additionally, kynurenic acid and kynurenine correlated statistically significantly with
eGFR and serum urea concentration. Other base covariates were not strongly correlated
to uremic solute concentrations.
Variability of uremic solute concentrations
Fig 3 shows scatter plots for uremic solute concentrations at the follow-up measurement
versus baseline concentration. On average, the mean solute levels were slightly higher at fol-
low-up. However, substantial variation was observed, which increased with higher concen-
trations. We calculated the mean difference and the limits of variation between baseline and
follow-up concentrations, which is shown in Table 3. The limits can be interpreted as the
bounds in which 95% of all differences between follow-up and baseline concentration will
fall. As uremic solute concentrations cannot be negative and their distributions were right
tailed, a relative measure of variability was more appropriate. Therefore, we repeated the
analysis using log-transformed concentrations. Back transformation gave values that can be
interpreted as a ratio between follow-up and baseline concentration. For example, the limits
Uremic Solutes in CKD
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of variation in hippuric acid concentration between baseline and follow-up were 0.24 and
5.6, respectively. Remarkably, tryptophan and its metabolites, indole-3-acetic acid and
kynurenine, showed least variation.
Fig 1. Flow chart for patient inclusion.
doi:10.1371/journal.pone.0168117.g001
Uremic Solutes in CKD
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Association between uremic solutes and progression of CKD
Table 4 shows the odds ratios for rapid progression by baseline serum uremic solute concen-
trations, crude and adjusted for potential confounders. None of the solutes were statistically
significantly associated to rapid progression in the crude analysis. Only indole-3-acetic acid
concentration was statistically significantly associated to rapid progression in the adjusted
analysis, with an adjusted OR of 2.07 (95% confidence interval 1.07 to 4.02) per incremental
Table 1. Baseline characteristics.
Variable Slow progressors (n = 40) Rapid progressors (n = 40)
mean / median SD / IQR mean / median SD / IQR p
Men 63% 75% 0.23
Age 64.9 (57.8–70.6) 57.1 (46.2–67.8) 0.07
Caucasians 88% 85% 0.75
Current smoker 23% 28% 0.61
Diabetes 20% 25% 0.59
ADPKD 8% 28% 0.02
Systolic blood pressure [mmHg] 139.6 19.1 139.7 24.1 0.98
Diastolic blood pressure mmHg] 78.5 (69.4–85.5) 82.4 (70.2–86.5) 0.18
eGFR [ml/min per 1.73m2] 35.7 (28.5–44.8) 36.3 (25.7–42.9) 0.65
Proteinuria [g/24h] 0.3 (0.2–0.7) 1.0 (0.2–2.3) 0.01
BMI [kg/m2] 27.5 4.2 26.5 3.5 0.26
Serum cholesterol [mM] 4.6 (4–5.3) 5.0 (4.3–5.9) 0.18
Serum albumin [g/l] 40.8 3.2 39.4 3.3 0.07
Serum calcium [mM] 2.3 0.1 2.3 0.1 0.50
Serum phosphate [mM] 1.0 (0.9–1.1) 1.1 (0.9–1.3) 0.26
Serum bicarbonate [mM] 24.8 3.8 23.9 3.2 0.26
Hb [mM] 8.4 0.9 8.1 1.1 0.21
PTH [pM] 7.2 (4.5–11) 10.2 (7.5–13.6) 0.01
Serum urea [mM] 10.7 (8.2–14.2) 12.6 (9.1–16.8) 0.50
Serum uric acid [mM] 0.4 0.1 0.5 0.1 0.05
Hb1Ac [%] 5.8 (5.5–6.3) 5.9 (5.6–6.6) 0.75
ACEi/ARB 85% 83% 0.76
Any BP lowering drugs 95% 93% 0.64
Anticoagulants 58% 53% 0.65
Vitamin D 13% 23% 0.24
Phosphate binders 5% 3% 0.56
Any lipid lowering drugs 68% 68% 1.00
ESA 5% 5% 1.00
Protein intake (g/d) 70.9 19.0 71.9 24.3 0.84
Fat intake (g/d) 67.3 (56–95.3) 76.1 (59.7–104) 0.49
Cholesterol intake (g/d) 154.9 (117.6–198.2) 168.3 (119.6–215.3) 0.49
Linoleic acid intake 13.2 5.8 13.8 6.1 0.67
Carbohydrate intake (g/d) 231.6 77.8 239.8 94.4 0.68
Dietary fiber intake (g/d) 19.7 (17.4–26.7) 19.6 (15.9–26.2) 0.82
Alcohol intake (g/d) 6.7 (0–17.1) 2.1 (.1–13.6) 0.49
Fluid intake (ml/d) 1691 (1375–2210.7) 1726 (1248.2–2199.6) 0.82
Data are presented as mean ± standard deviation, median (inter quartile range) and proportions. eGFR: estimated GFR, calculated using the abbreviated
Modified Diet in Renal Disease equation re-expressed for mass-spectrometry traceable serum creatinine concentration.
doi:10.1371/journal.pone.0168117.t001
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standard deviation in concentration. As a sensitivity analysis, the association between uremic
solute concentrations and change in eGFR as a continuous variable was also determined, but
appeared to be similar as presented in Table 5.
Discussion
Main findings
Advanced stages of chronic kidney disease are characterized by the retention and accumula-
tion of uremic solutes, yet it remains unclear whether uremic solutes are a product of CKD or
act as culprits in disease progression. The current study demonstrated that serum concentra-
tions of uremic solutes were elevated in patients with CKD compared to healthy persons.
Additionally, the results indicate that serum levels of several uremic solutes were generally not
associated with a rapidly progressive decline in eGFR over five years of follow-up within a
cohort of CKD patients with poor kidney function, possibly due to lack of power as a result of
small sample size, substantial between patient variation in solute concentrations and variable
solute concentrations within individual patients over time. Indole-3-acetic acid was seemingly
associated to rapid progression of CKD. However, the association was only present in the mul-
tivariate model, and no other uremic toxins were associated with rapid progression of CKD,
including those within the same metabolic pathway, most notably tryptophan. Therefore the
association between indole-3-acetic acid and progression may very well be the product of col-
lider bias. Finally, in all multivariate logistic regression models, low serum albumin, high pro-
teinuria and congential cause of kidney disease were associated with rapid progression of CKD
(data not shown).
Relation to other studies
Uremic solute concentrations are elevated in CKD stages 3 and 4. By showing that ure-
mic solutes are elevated in patients with moderate CKD, our results corroborate previous
work by others and ourselves.[5, 25, 26] Uremic solutes have been hypothesized to contribute
to eGFR decline in CKD. Uremic solutes, such as hippuric acid, indole-3-acetic acid, kynure-
nic acid have been shown to inhibit tubular excretion by competing for organic anion uptake
transporters and efflux pumps.[5, 27, 28] Therefore, elevated uremic solute plasma
Table 2. Uremic solute concentrations in CKD patients.
Uremic solute Reference* Slow progressors Rapid progressors
Mean (SD or range) Median IQR Median IQR p
CMPF [uM] 4.6 (4.2) 5.7 (2.7–14.9) 4.1 (1.7–8.3) 0.17
Hippuric acid [uM] 3.0 (0.0–5.0) 12.8 (5.5–24.5) 12.9 (5.9–24.9) 1.00
Indole acetic acid [uM] 0.05 (0.0–0.118) 3.4 (2.1–5.4) 4.2 (2.6–5.9) 0.17
Indoxyl sulfate [uM] 2.49 (1.36) 16.7 (10.3–21.8) 15.5 (8.8–22.2) 0.65
Kynurenic acid [nM] 230 (10) 122 (94–188) 154 (111–178) 0.07
Kynurenine [uM] 1.6 (0.1) 2.8 (2.4–3.3) 3.0 (2.4–3.6) 0.36
Quinolinic acid [uM] 0.47 (0.047) 0.7 (0.5–1) 0.9 (0.6–1.1) 0.26
p-Cresyl glucuronide [uM] 1.0 (0.7) 0.3 (0.1–0.6) 0.3 (0–0.7) 1.00
p-Cresyl sulfate [uM] n/a 42 (25–68) 49 (24–82) 0.17
Phenyl sulfate [uM] n/a 4.9 (2.6–8.2) 5.4 (3.4–11.6) 0.36
Tryptophan [uM] n/a 43 (33–49) 40 (30–47) 0.36
* Reference values were obtained from the Human Metabolome Database.[23] CMPF: 3-carboxy-4-methyl-5-propyl-2-furanpropionate.
doi:10.1371/journal.pone.0168117.t002
Uremic Solutes in CKD
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concentrations increase the risk of drug interactions and toxicity. Moreover, several uremic
solutes contribute to epithelial-to-mesenchymal transition in the renal tubule.[6–8] However,
elevated levels of these uremic solutes were not associated with a more rapid eGFR decline in
the present study. Overall, there is little evidence to support a direct effect of individual uremic
solutes on progressive eGFR decline in patients with moderate CKD.
Uremic solute concentrations vary greatly over time. Our findings indicate that intra-
individual uremic solute levels were highly variable. Eloot and colleagues have shown a large
variation in uremic solute concentrations between patients, and poor correlation between
eGFR and concentrations of several solutes.[29] Importantly, they showed that variability in
solute concentrations between patients increased with decreasing eGFR, reflected by increas-
ingly greater standard deviations. In a follow-up article the authors argued that this might
mean that, indices of tubular function become more important as renal failure progresses.[30]
Fig 2. Correlations between uremic solute concentrations and baseline covariates. The square root of the pearson’s R2 was
taken to achieve positive values. The black symbols mark correlations that were statistically significant at a nominal p<0.05 after
Bonferroni correction. DM: diabetes mellitus, Dx: congenital kidney disease, SBP: systolic blood pressure, DBP: diastolic blood
pressure, eGFR: estimated GFR, Uprot: proteinuria, BMI: body mass index, chol: serum cholesterol, alb: serum albumin, ca: serum
calcium, phos: serum phosphate, PTH: serum parathyroid hormone, UA: serum uric acid, RASi: renin-angiotensin inhibition,
BPdrugs: blood pressure lowering drugs, anti-coag: anti-coagulation, VitD: vitamin D use, phos binder: phosphate binder use, statin:
lipid lowerin drug use, ESA: erythropoiesis stimulating agent use, CMPF: 3-carboxy-4-methyl-5-propyl-2-furanpropionate, HA:
hippuric acid, IAA: indole-3-acetic acid, IS: indoxyl sulfate, KYNA: kynurenic acid, KYN: kynurenine, QA: quinolinic acid, PCG: p-
cresyl glucuronide, PCS: p-cresyl sulfate, PHS: phenyl sulfate, TRP: tryptophan, prot intake: dietary protein intake, sat fatty acid:
saturated fatty acid intake, MU fatty acid: mono unsaturated fatty acid intake, PU fatty acid: poly unsaturated fatty acid intake, carb
intake: carbohydrate intake, % fat: proportion of fat in diet, % protein: proportion protein in diet, % carbs: proportion carbohydrates in
diet, % unsat fat: proportion of poly unsaturated fatty acids of total fatty acid intake.
doi:10.1371/journal.pone.0168117.g002
Uremic Solutes in CKD
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This view is corroborated by the results of the IDEAL study, in which three quarters of all
patients randomized to a late start of hemodialysis, initiated dialysis prior to achieving the
Fig 3. Scatter plots for the concentration in uremic solute concentration at follow-up versus the baseline concentration.
The solid line represents the linear fit. Units are in μmol/l for all solutes except for kynurenic acid which was measured in nmol/l.
cmpf: 3-carboxy-4-methyl-5-propyl-2-furanpropionate, ha: hippuric acid, iaa: indole-3-acetic acid, is: indoxyl sulfate, kyna: kynurenic
acid, kyn: kynurenine, qa: quinolinic acid, pcg: p-cresyl glucuronide, pcs: p-cresyl sulfate, phs: phenyl sulfate, trp: tryptophan.
doi:10.1371/journal.pone.0168117.g003
Table 3. Variability of uremic solute concentrations.
Uremic solute Mean difference Limits of variation Antilog mean difference* Limits of variation
CMPF 1.0 -13 - 15 1.13 0.35 - 3.6
HA 4.7 -33 - 43 1.15 0.24 - 5.6
IAA 0.1 -3.8 - 4.0 1.05 0.53 - 2.1
IS 5.5 -20 - 31 1.29 0.43 - 3.9
KYNA 63 -222 - 349 1.23 0.51 - 3.0
KYN 0.5 -1.5 - 2.5 1.13 0.70 - 1.8
QA 0.5 -2.5 - 3.5 1.34 0.46 - 3.9
pCG 0.3 -1.9 - 2.4 1.48 0.11 - 19
pCS 13 -57 - 82 1.14 0.22 - 5.8
PHS 2.8 -14 - 20 1.35 0.28 - 6.6
TRP -1.4 -17 - 14 0.95 0.64 - 1.4
*The antilog can be interpreted as a ratio. The antilog of the mean difference was calculated by taking the natural logarithms of the baseline and follow-up
concentration for each patients. Then the difference between the two was calculated and the mean of these differences for all patients was estimated.
Subsequently, the antilog (exponent) of the difference was taken. CMPF: 3-carboxy-4-methyl-5-propyl-2-furanpropionate, HA: hippuric acid, IAA: indole-
3-acetic acid, IS: indoxyl sulfate, KYNA: kynurenic acid, KYN: kynurenine, QA: quinolinic acid, PCG: p-cresyl glucuronide, PCS: p-cresyl sulfate, PHS:
phenyl sulfate, TRP: tryptophan.
doi:10.1371/journal.pone.0168117.t003
Uremic Solutes in CKD
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target eGFR due to uremic symptoms.[31] GFR, and its decline, may not be the only important
outcome parameter in progressive CKD. Another, more recent, study reported variability of
uremic solute concentrations as well.[32] However, the authors used correlation coefficients to
assess variability, which reflects the presence of a linear association rather than variability.[24]
Moreover, correlation depended on the range of measurement. Therefore, substantial varia-
tion may still be present despite a strong correlation. In contrast, the limits of variability signi-
fied the maximum difference between uremic solute concentration at the first and second
measurement for 95% of the observations.[24] Our results show that the variability bands for
all solute levels were wide. The variability in uremic solute concentrations was evaluated at two
time points, one year apart. Therefore, it is unclear whether variability is the consequence of
Table 4. Odds ratio of rapid progression for a panel of uremic solutes.
Uremic Solute Crude Adjusted
OR 95% CI OR 95% CI
CMPF 0.78 0.48 - 1.29 0.94 0.49 - 1.81
Hippuric acid 1.20 0.76 - 1.90 1.50 0.77 - 2.93
Indole acetic acid 1.25 0.78 - 2.01 2.07 1.07 - 4.02
Indoxyl sulfate 0.84 0.52 - 1.33 0.96 0.54 - 1.70
Kynurenic acid 1.42 0.83 - 2.42 1.39 0.66 - 2.91
Kynurenine 1.24 0.78 - 1.99 1.37 0.76 - 2.48
Quinolinic acid 1.46 0.91 - 2.34 1.21 0.66 - 2.19
p-Cresyl glucuronide 0.90 0.57 - 1.42 0.97 0.51 - 1.84
p-Cresyl sulfate 1.14 0.72 - 1.79 1.38 0.76 - 2.53
Phenyl sulfate 1.12 0.71 - 1.78 1.29 0.72 - 2.32
Tryptophan 0.99 0.63 - 1.57 1.18 0.63 - 2.21
Odds ratios (OR) are presented per incremental SD in uremic solute concentration. The adjusted ORs were obtained from a logistic regression corrected for
batch, age, diagnosis (congenital disease present), systolic blood pressure, dietary fiber intake, protein intake, proteinuria and serum albumin concentration
at baseline. CMPF: 3-carboy-4-methyl-5-propyl-2-furanpropionate.
doi:10.1371/journal.pone.0168117.t004
Table 5. Baseline uremic toxin concentrations as predictors of eGFR decline.
Uremic Toxin Univariate Multivariate
Change in GFR 95%CI Change in GFR 95%CI
CMPF 0.63 -0.23 - 1.48 0.53 -0.34 - 1.40
Hippuric acid 0.02 -0.85 - 0.89 -0.14 -0.94 - 0.66
Indole acetic acid -0.38 -1.25 - 0.48 -0.95 -1.73 - -0.18
Indoxyl sulfate 0.49 -0.38 - 1.35 0.24 -0.55 - 1.03
Kynurenic acid -0.16 -1.03 - 0.71 -0.01 -0.96 - 0.93
Kynurenine -0.07 -0.94 - 0.80 -0.29 -1.06 - 0.48
Quinolinic acid -0.42 -1.28 - 0.45 -0.19 -0.96 - 0.59
p-Cresyl glucuronide 0.12 -0.75 - 0.98 0.10 -0.74 - 0.94
p-Cresyl sulfate -0.29 -1.16 - 0.57 -0.60 -1.40 - 0.20
Phenyl sulfate -0.14 -1.01 - 0.73 -0.34 -1.12 - 0.45
Tryptophan -0.09 -0.96 - 0.78 -0.26 -1.05 - 0.53
Change in eGFR is presented per incremental SD in uremic solute concentration. The adjusted changes in eGFR were obtained from a linear regression
corrected for batch, age, diagnosis (congenital disease present), systolic blood pressure, dietary fiber intake, protein intake, proteinuria and serum albumin
concentration at baseline. CMPF: 3-carboy-4-methyl-5-propyl-2-furanpropionate.
doi:10.1371/journal.pone.0168117.t005
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random, day-to-day variation, or indicative of a trend. However, in all likelihood, the variation
in uremic solute concentrations in the present study stems from changes in production and/or
absorption of solutes, and not from changes in excretion, as excretory function is unlikely to
vary to such a great extent within the individual patient. The variability of uremic solute levels
could result in regression dilution bias, and therefore in a false negative result if a relation is truly
present. On the other hand, random variation can also result in spurious associations, in particu-
lar when sample size is limited, giving rise to false positive results. Either way, any study where
uremic solutes were measured at a single point in time is difficult to interpret as a consequence.
Uremic solutes and progression of CKD. A recent study in a Chinese population of
CKD patients showed that p-cresyl sulfate and indoxyl sulfate were associated to renal progres-
sion and mortality.[33] Observed p-cresyl sulfate concentrations were comparable to those
found in our study. However, the estimated effect for p-cresyl sulfate was larger in the study by
Wu et al. In contrast to our study, the authors included patients with a wider GFR range.
Moreover, the baseline differences between patients showing progression and those who did
not were larger compared to our study. As a consequence, residual confounding may have
been present.
In an untargeted metabolic study, Niewczas et al. also found that baseline p-cresyl sulfate,
but not hippuric acid, was associated with progression to end stage renal disease in patients
with early stages of CKD.[32] Remarkably, they showed that in these patients, higher concen-
trations of tryptophan resulted in lower odds of progression. Likewise, Van der Kloet et al.
showed that the excretion of tryptophan and its metabolite kynurenic acid were increased in
diabetic patients who showed progressive increase in albuminuria.[34] In contrast, trypto-
phan, nor its metabolites kynurenine and kynurenic acid, associated with progression in our
hands. However, compared to the patients in the studies by Niewczas et al. and Van der Kloet
et al., our patients had more advanced CKD. Other metabolic pathways may play a role as
CKD progresses,[35] and therefore the effects of some solutes will only become prominent at
lower levels of GFR. For example, Wu et al. showed that both indoxyl sulfate and p-cresyl sul-
fate were only associated to renal progression and mortality in patients with GFR<45 ml/min
per 1.73m2. This suggests that GFR may be an effect modifier for the risk conveyed by uremic
solutes on renal progression. Under the sufficient cause model,[36] this would mean that p-
cresyl sulfate and indoxyl sulfate only result in renal progression if kidney damage is already
present. However, the findings of Wu et al. could not be reproduced in our study.
Strengths and limitations
A strong point of the present study is the prospective collection of all data and that samples
were obtained according to standard operating procedures. As a result, there was little missing
data and misclassification of categorical variables was unlikely. Additionally, uremic solutes
were measured at two points in time to study possible variation in uremic solute concentra-
tion. Assay variation was limited by including samples of individual patients in the same batch
and in the multivariate analysis we adjusted for between batch variation.
Nevertheless, the present study has its limitations. First, only eleven solutes out of the more
than 150 known solutes were studied. Moreover, only the effects of individual solutes on the
rate of progression were considered. Progression of CKD may be the result of several uremic
solutes acting together, either due to cumulative load of uremic solutes, or possibly through
synergistic effects. Furthermore, a biologically relevant solute may have been missed. Secondly,
in addition to extruding uremic solutes, the tubular epithelium removes other potentially toxic
compounds and drugs from the circulation.[37] As a result of the increased competition for
tubular transport, CKD patients may be at higher risk of drug interactions beyond the
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apparent risk due to a decreased GFR. This risk of drug interactions may result in more fre-
quent episodes of acute kidney injury. Such episodes may have gone undetected in the current
study, as serum creatinine was determined once every three months. Moreover, uremic solutes
can induce atherosclerosis.[6, 38, 39] Therefore, hypertension may occur and/or be more pro-
nounced, which in turn leads to a more rapid decrease in eGFR. Our follow-up may have been
too short, or the contrast in uremic solute exposure too subtle to study the long-term effects of
uremic solutes on hemodynamic changes and subsequent eGFR loss. Third, we have used the
abbreviated MDRD equation to estimate GFR. Although the eGFR-MDRD gives an unbiased
estimate of measured GFR in patients with CKD stages III to V, any GFR estimated from
serum creatinine is fairly insensitive to changes in eGFR over time.[40] This may have resulted
in an underestimation of the rate of GFR decline as well as misclassification of rapid progres-
sion. Fourth, the relatively low number of patients that were included in the study means that
statistical power was limited. The small sample size and high between patient variability of sol-
ute concentrations resulted in a small power to detect a statistically significant difference. A
rough post-hoc power calculation indicated that we had about 17% power to detect a statisti-
cally significant effect for a standard deviation increment in logged concentration on the rapid
progression of CKD. Low power may result in effect size overestimation, therefore the results
present here should be interpreted with caution. Fifth, tubular function and not GFR is
expected to be more strongly affected by elevated concentrations of uremic solutes. However,
in patients with stages III and IV CKD, progression is largely determined by factors causing
nephron loss, such as the primary kidney disease, hypertension and proteinuria. The number
of remaining, functional nephrons is reflected most accurately by GFR. In later stages of CKD,
when few functional nephrons remain, residual tubular function becomes more relevant.[27]
It determines the incidence of uremic symptoms, and therefore the onset and timing of renal
replacement therapy. In other words, uremic solutes may not be predictive of change in GFR
at early stages of CKD, but may very well predict the onset of end stage renal disease at later
stages of CKD. Furthermore, dietary intake of tryptophan and tyrosine containing products
are major sources for uremic solute formation. Food frequency questionnaires are known to
suffer from underreporting and recall bias, and therefore residual confounding due to misclas-
sification of dietary fiber and protein intake may be present. Finally, uremia has been associ-
ated with an altered gut microbiome composition and metabolism, which may include a
decrease in beneficial and an increase in potentially pathogenic gut microbiota members, and
an increase in the production of uremic toxins.[41, 42]
Future research
The present study has some major implications for future research. First and foremost, the day-
to-day variation in uremic solute concentrations and the determinants thereof remain to be elu-
cidated. Researchers may need to measure the levels of solutes over time, and take detailed ques-
tionnaires or journals on diet and food preparation to adequately study variation and its
determinants. Secondly, our findings imply that eGFR decline may not be a useful outcome in
trials intervening on the level of uremic solutes in patients with established CKD. Perhaps inves-
tigators should focus on other clinically relevant outcomes instead, such as the frequency of
complications, erythropoiesis stimulating agent use or health-related quality of life. Finally, it
remains unclear if solutes have independent, cumulative effects or that synergism may occur.
Conclusions
Serum uremic solutes concentrations are elevated in patients with CKD compared to healthy
individuals. However, the elevated levels of several uremic solutes in patients with CKD were
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not associated with a more rapid decline in eGFR over five years of follow-up, possibly due to
lack of power due to a combination of small sample size, high between patient variability of
uremic solute concentration, and high within patient variability over time. The latter compli-
cates the interpretation of studies that measure uremic solutes at a single time point and needs
to be elucidated.
Supporting Information
S1 Fig. Directed Acyclical graph for the analysis of uremic solutes as determinants of rapid
progression in CKD. The causal diagram show the hypothesized causal mechanism and mini-
mal adjustment set for the multivariate analyses. The open nodes indicate variables included
in the adjustment set. The grey nodes are unmeasured confounders. HbA1c is blue, as it is
assumed to be a mediator for the effect of uremic solutes.
(TIF)
S1 File. data_uremicsolutesinckd.dta. The analysis dataset used for all analyses described in
the present study.
(DTA)
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